Join to View Full Profile
1100 Fairview Ave N, D3-100Seattle, WA 98109
Phone+1 206-744-0208
Dr. Kimble is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Erik Kimble, MD, is a hematologist based in Seattle, WA with a subspecialty in Hematologic Oncology. He completed his residency in Internal Medicine at the University of Miami/Jackson Health System where he was chief resident, and then completed a fellowship in Hematology and Medical Oncology at the University of Washington and Fred Hutchinson Cancer Center. Dr. Kimble's experience includes handling cases of acute lymphoblastic leukemia, acute myeloblastic leukemia, and he is an expert in CAR T cell therapies. Additionally, he has made multiple contributions to medical literature, with his research often being cited by others.
Education & Training
University of WashingtonFellowship, Hematology and Medical Oncology, 2018 - 2021
University of Miami/Jackson Health SystemChief Residency, Internal Medicine, 2017 - 2018- University of Miami/Jackson Health SystemResidency, Internal Medicine, 2014 - 2017
Universidad de GuadalajaraClass of 2011
Certifications & Licensure
WA State Medical License 2018 - 2026
FL State Medical License 2017 - 2019
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- Real-world comparison of lisocabtagene maraleucel and axicabtagene ciloleucel in large B-cell lymphoma: an inverse probability of treatment weighting analysis with 3-y...Andrew J Portuguese, Jennifer J Huang, Yein Jeon, Mahnoosh Taheri, Aya Albittar
Haematologica. 2025-03-13 - Development and validation of predictive models of early immune effector cell-associated hematotoxicity.Emily C Liang, Jennifer J Huang, Andrew J Portuguese, Valentín Ortiz-Maldonado, Aya Albittar
Blood Advances. 2025-02-11 - Phase I study of CD19 CAR T-cell therapy harboring a fully human scFv in CAR-naïve adult B-ALL patients.Jordan Gauthier, Emily C Liang, Jennifer J Huang, Erik Lesley Kimble, Alexandre V Hirayama
Blood Advances. 2025-01-16
Professional Memberships
- Member
- American Sociey for Transplantation and Cellular TherapyMember
- Member
- American Society of Gene and Cell TherapyMember
Other Languages
- Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
